Amvuttra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advances in rna interference technology, unmet needs in ttr amyloidosis, regulatory approvals for sirna drugs, increased rare disease awareness, specialist adoption of targeted therapies.

The growth in the forecast period can be attributed to expansion of rna based pipelines, rising diagnosis rates of amyloidosis, improved genetic screening, increased orphan drug funding, long term efficacy data generation. Major trends in the forecast period include growth of sirna based therapies, expansion of disease modifying amyloidosis treatments, increased focus on genetic rare disorders, hospital centered advanced rna therapeutics, long term neurological outcome management.

The growing demand for personalized medicine is expected to drive the expansion of the amvuttra market in the coming years. Personalized medicine is a healthcare approach that customizes treatments for individual patients based on their genetic, environmental, and lifestyle characteristics to optimize therapeutic outcomes and improve quality of care. Demand for personalized medicine is increasing due to advancements in genomic technologies, which allow for precise identification of genetic variations and the development of tailored treatment strategies. Amvuttra supports personalized medicine by delivering a gene-silencing therapy specifically designed to target and reduce transthyretin (TTR) protein production in patients with hereditary ATTR amyloidosis. It provides a mutation-specific, precision-based treatment that enhances clinical outcomes while enabling individualized patient care. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a substantial increase from 12 approvals in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the amvuttra market.

Leading companies operating in the amvuttra market are concentrating on the development of advanced RNA-silencing therapies to improve long-term effectiveness and expand patient access. RNA interference (RNAi) is a biological process in which small interfering RNA molecules selectively target and degrade messenger RNA, thereby reducing the production of disease-causing proteins and enabling sustained protein suppression with infrequent dosing. For example, in March 2025, US-based Alnylam received FDA approval for Amvuttra (vutrisiran) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and subsequently launched the therapy. Key attributes include a competitive gene-silencing mechanism, strong patient demand, a buy-and-bill reimbursement model, rapid adoption across both academic and community care settings, coverage across more than 170 priority US health systems, and 48-month HELIOS-B clinical trial data demonstrating a 37% relative risk reduction in cardiovascular events.

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, expanded its partnership with Alnylam Pharmaceuticals Inc. to enhance global access to Alnylam’s innovative RNAi therapies for patients with rare diseases. This collaboration leverages Medison’s integrated commercialization platform across multiple regions, including Latin America (LATAM), the Asia-Pacific (APAC), and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures Amvuttra.

Major companies operating in the amvuttra market are Alnylam Pharmaceuticals Inc.

North America was the largest region in the amvuttra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amvuttra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the amvuttra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the amvuttra market by increasing costs associated with imported rna synthesis materials and specialized pharmaceutical manufacturing equipment. These impacts are most visible in specialty hospitals and rare disease treatment centers across north america and europe. Higher import duties have contributed to elevated therapy pricing and reimbursement complexity. Supply chain timelines have also been affected by cross border regulatory clearances. At the same time, tariffs are encouraging regional production of rna therapeutics and strengthening long term supply resilience.

The amvuttra market research report is one of a series of new reports that provides amvuttra market statistics, including amvuttra industry global market size, regional shares, competitors with a amvuttra market share, detailed amvuttra market segments, market trends and opportunities, and any further data you may need to thrive in the amvuttra industry. This amvuttra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Amvuttra is a prescription small interfering RNA (siRNA) therapy developed to lower the production of transthyretin (TTR) protein in the liver. By selectively targeting and degrading the messenger RNA (mRNA) involved in TTR synthesis, amvuttra helps inhibit the formation of amyloid deposits. The therapy is intended to reduce symptoms such as pain, weakness, and limited mobility, thereby stabilizing or improving the patient’s overall quality of life.

The primary indication for amvuttra is hereditary transthyretin-mediated amyloidosis, including adult polyneuropathy and cardiomyopathy. Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare genetic condition caused by mutations in the TTR gene, resulting in abnormal protein accumulation that damages nerves, the heart, and other organs. The treatment is distributed through multiple channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patient populations.

The amvuttra market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.